---
title: "Tango Therapeutics, Inc. (TNGX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TNGX.US.md"
symbol: "TNGX.US"
name: "Tango Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T14:41:16.859Z"
locales:
  - [en](https://longbridge.com/en/quote/TNGX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TNGX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TNGX.US.md)
---

# Tango Therapeutics, Inc. (TNGX.US)

## Company Overview

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.tangotx.com](https://www.tangotx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.43)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 83 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 39.04% |  |
| Net Profit YoY | 18.93% |  |
| P/B Ratio | 7.48 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2928118101.30 |  |
| Revenue | 56992000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -38.42% | E |
| Profit Margin | -188.15% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 39.04% | A |
| Net Profit YoY | 18.93% | B |
| Total Assets YoY | 58.87% | A |
| Net Assets YoY | 134.78% | A |
| Cash Flow Margin | 132.00% | B |
| OCF YoY | 39.04% | A |
| Turnover | 0.16 | D |
| Gearing Ratio | 10.16% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tango Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "39.04%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.48",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2928118101.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "56992000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-38.42%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-188.15%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "39.04%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.93%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "58.87%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "134.78%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "132.00%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "39.04%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.16",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.16%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -27.31 | 518/386 | - | - | - |
| PB | 7.48 | 377/386 | 9.59 | 7.18 | 4.43 |
| PS (TTM) | 51.38 | 231/386 | 42.73 | 25.54 | 16.66 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 75% |
| Hold | 3 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.63 |
| Highest Target | 55.00 |
| Lowest Target | 21.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TNGX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TNGX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TNGX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TNGX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**